An integrated neuroimaging-omics approach for the gut-brain communication pathways in Alzheimer’s disease

Frontiers in Aging Neuroscience

Aging Neuroscience

Wenying Du¹  Xiaoni Wang²  Qingqing Ding³  Peng Xu³  Xue Chen³  Can Sheng³  Yuan Liang³  Shulei Jia⁴ 

[1] Department of Neurology, China-Japan Friendship Hospital, Beijing, China;Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China;Department of Neurology, The Affiliated Hospital of Jining Medical University, Jining, China;Institute of Microbiology, Chinese Academy of Sciences, Beijing, China;

关键词: Alzheimer’s disease;    microbiome;    metabolome;    neuroimaging;    microbiota-gut-brain axis;   

DOI  :  10.3389/fnagi.2023.1211979

 received in 2023-04-25, accepted in 2023-09-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

A key role of the gut microbiota in the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease (AD), has been identified over the past decades. Increasing clinical and preclinical evidence implicates that there is bidirectional communication between the gut microbiota and the central nervous system (CNS), which is also known as the microbiota-gut-brain axis. Nevertheless, current knowledge on the interplay between gut microbiota and the brain remains largely unclear. One of the primary mediating factors by which the gut microbiota interacts with the host is peripheral metabolites, including blood or gut-derived metabolites. However, mechanistic knowledge about the effect of the microbiome and metabolome signaling on the brain is limited. Neuroimaging techniques, such as multi-modal magnetic resonance imaging (MRI), and fluorodeoxyglucose-positron emission tomography (FDG-PET), have the potential to directly elucidate brain structural and functional changes corresponding with alterations of the gut microbiota and peripheral metabolites in vivo. Employing a combination of gut microbiota, metabolome, and advanced neuroimaging techniques provides a future perspective in illustrating the microbiota-gut-brain pathway and further unveiling potential therapeutic targets for AD treatments.

【 授权许可】

Unknown   
Copyright © 2023 Sheng, Du, Liang, Xu, Ding, Chen, Jia and Wang.